Eurofin Announces Exova Purchase
Eurofins Scientific has announced the purchase of Exova’s environment testing business located in Eastern Canada in a deal estimated to be worth $13 million CAD.
Eurofins Scientific has announced the purchase of Exova’s environment testing business located in Eastern Canada in a deal estimated to be worth $13 million CAD. The purchase represents an expansion of Canadian investment following on from Eurofins’s earlier purchase of Experchem, a laboratory focused on nutraceuticals testing, in May 2015.
Consisting of around 160 employees and five laboratories across Quebec and Ontario, Exova’s laboratories serve large industrial companies, local authorities, and consultants and offer a range of analytical services and distribution channels throughout Eastern Canada.
“The five Exova laboratories in Quebec and Ontario that just joined our Group represent a good strategic fit for Eurofins as they accelerate the deployment of our environment testing capabilities in Canada,” said Gilles Martin, Eurofins CEO.
For more information, please visit: www.eurofins.com
Understanding FDA Recommendations for N-Nitrosamine Impurity Levels
April 17th 2025We spoke with Josh Hoerner, general manager of Purisys, which specializes in a small volume custom synthesis and specialized controlled substance manufacturing, to gain his perspective on FDA’s recommendations for acceptable intake limits for N-nitrosamine impurities.
University of Rouen-Normandy Scientists Explore Eco-Friendly Sampling Approach for GC-HRMS
April 17th 2025Root exudates—substances secreted by living plant roots—are challenging to sample, as they are typically extracted using artificial devices and can vary widely in both quantity and composition across plant species.
Determining the Serum Proteomic Profile in Migraine Patients with LC–MS
April 17th 2025Researchers used liquid chromatography–mass spectrometry (LC–MS) in their proteomic analysis to compare the serum proteome of migraine patients with healthy controls and to identify differentially expressed proteins as potential migraine biomarkers.
